Barasch, A., Cunha-Cruz, J., Curro, F.A., Hujoel, P., Sung, A.H., Vena, D., Voinea-Griffin, A.E. (CONDOR Collaborative Group) Beadnell, S., Craig, R.G., DeRouen, T., Desaranayake, A., Gilbert, A., Gilbert, G.H., Gold- berg, K., Hauley, R., Hashimoto, M., Holmes, J., Latzke, B., Leroux, B., Lindblad, A., Richman, J., Safford, M., Ship, J., Thompson, V.P., Williams, O.D. and Yin, W. (2011) Risk factors for osteonecrosis of the jaws: A case-control study from the CONDOR dental PBRN. Journal of Dental Research, 90, 439-444. doi:10.1177/0022034510397196

has been cited by the following article:

• TITLE: Bisphosphonate-related osteonecrosis of the jaws: A report on 30 cases

  AUTHORS: Mario Migliario, Andrea Melle, Vittorio Fusco, Lia Rimondini

  KEYWORDS: Bisphosphonates; Jaws; Osteonecrosis; Panoramic Radiograph; Dental Hygiene

  JOURNAL NAME: Open Journal of Stomatology, Vol.3 No.4, July 22, 2013

  ABSTRACT: Aim: To report a series of thirty cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: For 30 patients with BRONJ, gender, age, underlying diagnosis, type of bisphosphonate (BP), administration route and duration, location and stage of osteonecrosis, symptoms and oral health status, radiological findings of the jaws, treatment and outcome, were recorded. Results: Underlying diagnoses in the series (12 male; 18 female; mean age 70.50 ± 9.62) were: 12 multiple myeloma, 7 breast cancer, 3 prostate carcinoma, 1 kidney/lung/ bladder/mediastinal cancer, 1 chronic lymphocytic leukemia, 1 osteoporosis, 1 palatal osteosarcoma + osteoporosis, 1 non-Hodgkin’s lymphoma. Forty-seven osteonecrotic lesions were detected; 30 localized in the mandible,17 inthe maxilla; trigger events were tooth extraction in 31 cases (66%), periodontal disease in 4 (8.50%), incongruous dentures in 3 (6.40%), perimplantitis in 1 (2.10%), unknown in 8 (17%). Twenty-nine patients had received treatment using amino bisphosphonates (25 zoledronate, 2 pamidronate, 2 alendronate) and 1 clodronate; the administration route was intravenous in 27 patients, oral in 2 and intramuscular in 1. Mean number of doses to bone exposure for patients was 34.11 for zoledronate, 50.50 for pamidronate, 146 for alendronate, and 500 for clodronate. Among statistical data the only significant finding was that panoramic dental radiography gave no concrete support for diagnosis of ONJ lesions (p ≤ 0.04). Conclusions: Our case series reflects literature data. We emphasize the insufficient role of panoramic radiography to study osteonecrotic lesions and the role of poor oral hygiene.